JP2023553935A - 脱アミノ化を伴うゲノム編集のためのポリヌクレオチド、組成物、及び方法 - Google Patents

脱アミノ化を伴うゲノム編集のためのポリヌクレオチド、組成物、及び方法 Download PDF

Info

Publication number
JP2023553935A
JP2023553935A JP2023535332A JP2023535332A JP2023553935A JP 2023553935 A JP2023553935 A JP 2023553935A JP 2023535332 A JP2023535332 A JP 2023535332A JP 2023535332 A JP2023535332 A JP 2023535332A JP 2023553935 A JP2023553935 A JP 2023553935A
Authority
JP
Japan
Prior art keywords
chr7
mrna
cell
sequence
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553935A5 (cg-RX-API-DMAC10.html
Inventor
ドムブロウスキ,クリスチャン
ハリントン,ウィリアム,フレデリック
オリベイラ,ルアン
Original Assignee
インテリア セラピューティクス,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インテリア セラピューティクス,インコーポレイテッド filed Critical インテリア セラピューティクス,インコーポレイテッド
Publication of JP2023553935A publication Critical patent/JP2023553935A/ja
Publication of JP2023553935A5 publication Critical patent/JP2023553935A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04005—Cytidine deaminase (3.5.4.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/539—Deaminase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023535332A 2020-12-11 2021-12-10 脱アミノ化を伴うゲノム編集のためのポリヌクレオチド、組成物、及び方法 Pending JP2023553935A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063124060P 2020-12-11 2020-12-11
US63/124,060 2020-12-11
US202063130104P 2020-12-23 2020-12-23
US63/130,104 2020-12-23
US202163165636P 2021-03-24 2021-03-24
US63/165,636 2021-03-24
US202163275424P 2021-11-03 2021-11-03
US63/275,424 2021-11-03
PCT/US2021/062922 WO2022125968A1 (en) 2020-12-11 2021-12-10 Polynucleotides, compositions, and methods for genome editing involving deamination

Publications (2)

Publication Number Publication Date
JP2023553935A true JP2023553935A (ja) 2023-12-26
JP2023553935A5 JP2023553935A5 (cg-RX-API-DMAC10.html) 2025-09-04

Family

ID=80118959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535332A Pending JP2023553935A (ja) 2020-12-11 2021-12-10 脱アミノ化を伴うゲノム編集のためのポリヌクレオチド、組成物、及び方法

Country Status (13)

Country Link
US (1) US20240002820A1 (cg-RX-API-DMAC10.html)
EP (1) EP4259792A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023553935A (cg-RX-API-DMAC10.html)
KR (1) KR20230129996A (cg-RX-API-DMAC10.html)
AU (1) AU2021394998A1 (cg-RX-API-DMAC10.html)
CA (1) CA3205000A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023001684A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023009114A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230305A (cg-RX-API-DMAC10.html)
IL (1) IL303506A (cg-RX-API-DMAC10.html)
MX (1) MX2023006876A (cg-RX-API-DMAC10.html)
TW (1) TW202237845A (cg-RX-API-DMAC10.html)
WO (1) WO2022125968A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024541962A (ja) * 2021-11-03 2024-11-13 インテリア セラピューティクス,インコーポレイテッド 遺伝子編集のための修飾ガイドrna

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3220738A1 (en) * 2021-05-21 2022-11-24 Beam Therapeutics Inc. Base editing of transthyretin gene
TW202317764A (zh) * 2021-06-10 2023-05-01 美商英特利亞醫療公司 用於基因編輯之包含內部連接子之經修飾引導rna
EP4426822A2 (en) * 2021-11-03 2024-09-11 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for genome editing
WO2024006955A1 (en) 2022-06-29 2024-01-04 Intellia Therapeutics, Inc. Engineered t cells
EP4638783A2 (en) 2022-12-22 2025-10-29 Intellia Therapeutics, Inc. Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies
WO2024227082A1 (en) * 2023-04-26 2024-10-31 Vijay Sankaran Base-editing perturbation screens and uses thereof
WO2025038637A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
TW202515994A (zh) 2023-08-14 2025-04-16 美商英特利亞醫療公司 用於對cd70進行基因修飾之組合物及方法
WO2025081064A2 (en) * 2023-10-11 2025-04-17 Illumina, Inc. Thermophilic deaminase and methods for identifying modified cytosine
KR20260062985A (ko) * 2023-10-13 2026-05-07 스마트셀라 솔루션즈 아베 중간엽 줄기세포를 이용한 비변형 mRNA 작제물의 전달을 위한 방법 및 조성물
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
IL330230A (en) 2023-12-20 2026-08-01 Intellia Therapeutics Inc Engineered T cells
WO2025255308A1 (en) 2024-06-07 2025-12-11 Intellia Therapeutics, Inc. Cd8 co-receptor chimeric polypeptides in tcr cell therapy
TW202617987A (zh) * 2024-06-26 2026-05-01 美商英特利亞醫療公司 用於基因體編輯之經修飾之嚮導rna
WO2026143185A1 (en) 2024-12-23 2026-07-02 Ensoma Aps Engineered rna-guided dna-binding polypeptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019516351A (ja) * 2016-03-30 2019-06-20 インテリア セラピューティクス,インコーポレイテッド Crispr/cas構成成分のための脂質ナノ粒子製剤

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
ATE515510T1 (de) 1991-12-24 2011-07-15 Isis Pharmaceuticals Inc Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
EP0760008A1 (en) 1994-05-19 1997-03-05 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
WO2001075436A1 (en) 2000-04-03 2001-10-11 Board Of Trustees Of The Leland Stanford Junior University A method for protein structure alignment
WO2006007712A1 (en) 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
US7774185B2 (en) 2004-09-14 2010-08-10 International Business Machines Corporation Protein structure alignment using cellular automata
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
AU2016226077B2 (en) 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
DK4276189T3 (da) 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
JP2019515914A (ja) 2016-04-22 2019-06-13 インテリア セラピューティクス,インコーポレイテッド 転写因子4内のトリヌクレオチドリピートと関連する疾患の治療のための組成物および方法
EP3551757A1 (en) 2016-12-08 2019-10-16 Intellia Therapeutics, Inc. Modified guide rnas
JP7383478B2 (ja) 2016-12-22 2023-11-20 インテリア セラピューティクス,インコーポレイテッド アルファ1アンチトリプシン欠乏症を治療するための組成物および方法
WO2019041296A1 (zh) * 2017-09-01 2019-03-07 上海科技大学 一种碱基编辑系统及方法
EP3688162B1 (en) 2017-09-29 2024-03-06 Intellia Therapeutics, Inc. Formulations
TWI904069B (zh) 2017-09-29 2025-11-11 美商英特利亞醫療公司 用於ttr基因編輯及治療attr澱粉樣變性之組合物及方法
JP7832761B2 (ja) 2018-06-08 2026-03-18 インテリア セラピューティクス,インコーポレイテッド 遺伝子編集のための修飾されたガイドrna
MX2021001070A (es) 2018-07-31 2021-05-27 Intellia Therapeutics Inc Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1).
JP7541508B2 (ja) * 2018-08-23 2024-08-28 サンガモ セラピューティクス, インコーポレイテッド 操作された標的特異的な塩基エディター
MX2021003455A (es) 2018-10-02 2021-09-21 Intellia Therapeutics Inc Lípidos con amina ionizables.
CN113166743B (zh) 2018-10-15 2026-04-07 马萨诸塞大学 Nme2cas9-脱氨酶融合蛋白的可编程dna碱基编辑
CN119285480A (zh) 2018-12-05 2025-01-10 英特利亚治疗股份有限公司 改性的胺脂质
KR20210116526A (ko) * 2019-01-16 2021-09-27 빔 테라퓨틱스, 인크. 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포
MX2021011690A (es) * 2019-03-28 2022-01-06 Intellia Therapeutics Inc Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr que comprende un corticosteroide o uso de este.
WO2020219876A1 (en) 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019516351A (ja) * 2016-03-30 2019-06-20 インテリア セラピューティクス,インコーポレイテッド Crispr/cas構成成分のための脂質ナノ粒子製剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIJIE WANG ET AL., CELL RESEARCH, vol. 27, no. 10, JPN6025053601, 2017, pages 1289 - 1292, ISSN: 0005765713 *
YUNQING MA ET AL., NATURE METHODS, vol. 13, no. 12, JPN6025053600, 2016, pages 1029 - 1035, ISSN: 0005765712 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024541962A (ja) * 2021-11-03 2024-11-13 インテリア セラピューティクス,インコーポレイテッド 遺伝子編集のための修飾ガイドrna

Also Published As

Publication number Publication date
EP4259792A1 (en) 2023-10-18
MX2023006876A (es) 2023-07-31
IL303506A (en) 2023-08-01
WO2022125968A1 (en) 2022-06-16
CR20230305A (es) 2023-11-10
CL2023001684A1 (es) 2024-01-05
CO2023009114A2 (es) 2023-08-18
US20240002820A1 (en) 2024-01-04
KR20230129996A (ko) 2023-09-11
AU2021394998A9 (en) 2024-05-02
TW202237845A (zh) 2022-10-01
CA3205000A1 (en) 2022-06-16
AU2021394998A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
US20240002820A1 (en) Polynucleotides, Compositions, and Methods for Genome Editing Involving Deamination
US12595478B2 (en) Crispr-Cas systems having destabilization domain
US11827877B2 (en) Compositions and methods for genomic editing by insertion of donor polynucleotides
Andries et al. N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice
JP7636338B2 (ja) コルチコステロイドを含む、ttr遺伝子編集およびattrアミロイドーシスを治療するための組成物および方法、またはその使用
BR112020005323A2 (pt) polinucleotídeos, composições e métodos para edição de genoma
TW201802242A (zh) Crispr/cas組分之脂質奈米粒子調配物
CN113874076A (zh) 包括ttr向导rna和对rna引导的dna结合剂进行编码的多核苷酸的组合物和方法
AU2015369725A1 (en) CRISPR having or associated with destabilization domains
JP2020535805A (ja) 細胞の遺伝子修飾のための非組込みdnaベクター
US20240301377A1 (en) Polynucleotides, Compositions, and Methods for Genome Editing
US20240167008A1 (en) Novel crispr enzymes, methods, systems and uses thereof
US20220228147A1 (en) Uses of trem compositions to modulate trna pools
Tasca et al. High-capacity adenovector delivery of forced CRISPR-Cas9 heterodimers fosters precise chromosomal deletions in human cells
WO2023019269A2 (en) Novel omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 and 259 crispr nucleases
CN117280024A (zh) 用于涉及脱氨作用的基因组编辑的多核苷酸、组合物和方法
AU2023295529A1 (en) Methods and compositions for genetically modifying a cell
KR20240038705A (ko) 간 유전자의 생체 내 편집 방법
CN118660960A (zh) 用于基因组编辑的多核苷酸、组合物和方法
HK40103082A (en) Polynucleotides, compositions, and methods for genome editing involving deamination
US20240425850A1 (en) Noncanonical crRNA for Highly Efficient Genome Editing
WO2026006390A2 (en) Modified guide rnas for genome editing
Economos Peptide Nucleic Acids and CRISPR-Cas9: Mechanisms and Rational Applications for Gene Editing Systems
HK40065742A (en) Compositions and methods for ttr gene editing and treating attr amyloidosis comprising a corticosteroid or use thereof
HK40114401A (en) Polynucleotides, compositions, and methods for genome editing

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260706